Richard A. Heyman

Biochemistry, Genetics and Molecular Biology · Life Sciences

60h-index20.5kcitations129works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Estrogen and related hormone effects(61), Retinoids in leukemia and cellular processes(54), Peroxisome Proliferator-Activated Receptors(24), Prostate Cancer Treatment and Research(19), Antioxidant Activity and Oxidative Stress(18)

Publications128 total

Supplementary Tables 1-7 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 3 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Methods from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 1 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 2 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 2 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Methods from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 4 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Tables 1-7 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 4 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Data from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 5 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 5 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Data from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 1 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
Supplementary Figure 3 from ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
2023Open Access
POSTINDUSTRIAL PARK OR BOURGEOIS PLAYGROUND?
University of Arizona Press eBooks·2021
Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
eLife·2019· 7 citedOpen Access
Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927
ACS Medicinal Chemistry Letters·2018· 74 citedOpen Access
Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer
Journal of Medicinal Chemistry·2018· 37 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

David J. Mangelsdorf(10), Ronald M. Evans(9), Ira G. Schulman(7), Eric D. Bischoff(7), Peter J. Davies(5), Marcus F. Boehm(5), Jing Qian(4), Peter Ordentlich(4), László Nagy(4), William W. Lamph(4), Roshantha A.S. Chandraratna(4), Christopher K. Glass(3), Michael G. Rosenfeld(3), Johan Auwerx(3), James D. Joseph(3), Kate Grillot(3), Anna Aparicio(3), Gang Shao(3), John Sensintaffar(3), Céline Bonnefous(3)